Adalimumab exemptia (ZYDUS)
Adalimumab Exemptia is a highly effective biologic medication developed to manage chronic autoimmune conditions by targeting tumor necrosis factor-alpha (TNF-alpha), a key contributor to inflammation. It helps reduce pain, swelling, and joint damage in conditions such as rheumatoid arthritis, psoriasis, and ankylosing spondylitis. Manufactured by Zydus, this pre-filled injection offers consistent quality and reliable therapeutic outcomes. The treatment supports long-term disease control, improves physical function, and enhances overall quality of life. Suitable for patients requiring advanced biologic therapy, it is widely trusted for its safety profile and effectiveness when used under proper medical supervision.
Description
Adalimumab Exemptia is a biologic medication developed by Zydus to help manage various chronic autoimmune conditions by controlling excessive inflammation in the body. It contains adalimumab as its active ingredient, which works as a tumor necrosis factor-alpha (TNF-alpha) inhibitor. TNF-alpha plays an important role in triggering inflammation, and this therapy helps reduce its activity to support better disease control.
Healthcare professionals prescribe Adalimumab Exemptia for conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, Crohn’s disease, and ulcerative colitis. By reducing inflammatory responses, it helps relieve symptoms like joint pain, swelling, stiffness, and skin-related complications associated with autoimmune disorders. The medication supports improved mobility, physical function, and overall patient well-being when used as directed by a qualified healthcare provider.
Zydus manufactures this advanced biologic treatment using quality-controlled processes to ensure consistency and reliability. The pre-filled injection format provides convenient administration and helps patients follow their prescribed treatment schedules effectively. Doctors determine the appropriate dosage and duration of therapy based on the patient’s medical condition, response to treatment, and individual healthcare needs.
Adalimumab Exemptia provides targeted action by affecting specific immune pathways rather than broadly suppressing the immune system. This focused approach helps manage inflammation while supporting long-term disease management. Patients should follow their doctor’s instructions regarding administration, storage, and regular monitoring during treatment.
This medication requires proper medical supervision because biologic therapies can influence immune responses. Patients should inform their healthcare provider about existing medical conditions, ongoing medications, or any history of infections before starting therapy. With appropriate guidance and regular follow-up, this treatment can help patients achieve better control over autoimmune conditions and improve their quality of life.
- Brand Name: Exemptia
- Generic Name: Adalimumab
- Manufacturer: Zydus Cadila
- Drug Class: TNF-Alpha Inhibitor
- Form: Pre-filled Injection
- Strength: 40 mg
- Route of Administration: Subcutaneous
- Indications: Rheumatoid arthritis, psoriasis, ankylosing spondylitis, Crohn’s disease
- Prescription Required: Yes
- Storage: Store in a refrigerator (2°C to 8°C), do not freeze
